TY - JOUR
T1 - Notch signaling drives intestinal graft-versus-host disease in mice and nonhuman primates
AU - Tkachev, Victor
AU - Vanderbeck, Ashley
AU - Perkey, Eric
AU - Furlan, Scott N.
AU - McGuckin, Connor
AU - Atria, Daniela Gómez
AU - Gerdemann, Ulrike
AU - Rui, Xianliang
AU - Lane, Jennifer
AU - Hunt, Daniel J.
AU - Zheng, Hengqi
AU - Colonna, Lucrezia
AU - Hoffman, Michelle
AU - Yu, Alison
AU - Outen, Riley
AU - Kelly, Samantha
AU - Allman, Anneka
AU - Koch, Ute
AU - Radtke, Freddy
AU - Ludewig, Burkhard
AU - Burbach, Brandon
AU - Shimizu, Yoji
AU - Panoskaltsis-Mortari, Angela
AU - Chen, Guoying
AU - Carpenter, Stephen M.
AU - Harari, Olivier
AU - Kuhnert, Frank
AU - Thurston, Gavin
AU - Blazar, Bruce R.
AU - Kean, Leslie S.
AU - Maillard, Ivan
N1 - Publisher Copyright:
Copyright © 2023 The Authors, some rights reserved.
PY - 2023
Y1 - 2023
N2 - Notch signaling promotes T cell pathogenicity and graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (allo-HCT) in mice, with a dominant role for the Delta-like Notch ligand DLL4. To assess whether Notch’s effects are evolutionarily conserved and to identify the mechanisms of Notch signaling inhibition, we studied antibody-mediated DLL4 blockade in a nonhuman primate (NHP) model similar to human allo-HCT. Short-term DLL4 blockade improved posttransplant survival with durable protection from gastrointestinal GVHD in particular. Unlike prior immunosuppressive strategies tested in the NHP GVHD model, anti-DLL4 interfered with a T cell transcriptional program associated with intestinal infiltration. In cross-species investigations, Notch inhibition decreased surface abundance of the gut-homing integrin α4β7 in conventional T cells while preserving α4β7 in regulatory T cells, with findings suggesting increased β1 competition for α4 binding in conventional T cells. Secondary lymphoid organ fibroblastic reticular cells emerged as the critical cellular source of Delta-like Notch ligands for Notch-mediated up-regulation of α4β7 integrin in T cells after allo-HCT. Together, DLL4-Notch blockade decreased effector T cell infiltration into the gut, with increased regulatory to conventional T cell ratios early after allo-HCT. Our results identify a conserved, biologically unique, and targetable role of DLL4-Notch signaling in intestinal GVHD.
AB - Notch signaling promotes T cell pathogenicity and graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (allo-HCT) in mice, with a dominant role for the Delta-like Notch ligand DLL4. To assess whether Notch’s effects are evolutionarily conserved and to identify the mechanisms of Notch signaling inhibition, we studied antibody-mediated DLL4 blockade in a nonhuman primate (NHP) model similar to human allo-HCT. Short-term DLL4 blockade improved posttransplant survival with durable protection from gastrointestinal GVHD in particular. Unlike prior immunosuppressive strategies tested in the NHP GVHD model, anti-DLL4 interfered with a T cell transcriptional program associated with intestinal infiltration. In cross-species investigations, Notch inhibition decreased surface abundance of the gut-homing integrin α4β7 in conventional T cells while preserving α4β7 in regulatory T cells, with findings suggesting increased β1 competition for α4 binding in conventional T cells. Secondary lymphoid organ fibroblastic reticular cells emerged as the critical cellular source of Delta-like Notch ligands for Notch-mediated up-regulation of α4β7 integrin in T cells after allo-HCT. Together, DLL4-Notch blockade decreased effector T cell infiltration into the gut, with increased regulatory to conventional T cell ratios early after allo-HCT. Our results identify a conserved, biologically unique, and targetable role of DLL4-Notch signaling in intestinal GVHD.
UR - http://www.scopus.com/inward/record.url?scp=85163601186&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85163601186&partnerID=8YFLogxK
U2 - 10.1126/scitranslmed.add1175
DO - 10.1126/scitranslmed.add1175
M3 - Article
C2 - 37379368
AN - SCOPUS:85163601186
SN - 1946-6234
VL - 15
JO - Science Translational Medicine
JF - Science Translational Medicine
IS - 702
M1 - eadd1175
ER -